G Schernthaner
Overview
Explore the profile of G Schernthaner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
316
Citations
2854
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hambling C, Khunti K, Cos X, Wens J, Martinez L, Topsever P, et al.
Prim Care Diabetes
. 2019 Feb;
13(4):330-352.
PMID: 30792156
Diabetes in later life is associated with a range of factors increasing the complexity of glycaemic management. This position statement, developed from an extensive literature review of the subject area,...
2.
Holden S, Jenkins-Jones S, Morgan C, Peters J, Schernthaner G, Currie C
Diabet Med
. 2017 Feb;
34(6):770-780.
PMID: 28173634
Aims: To characterize the prevalence of Type 2 diabetes between 1991 and 2013 in the UK and to determine whether corresponding glucose control and survival had changed in the diabetic...
3.
Schernthaner G, Schernthaner G
Herz
. 2016 Apr;
41(3):208-16.
PMID: 27071968
Prevention of cardiovascular morbidity and mortality remains the key factor in the treatment of type 2 diabetes (T2DM). In the early phase of T2DM, multifactorial intervention is mandatory and glucose...
4.
Clemens K, Liu K, Shariff S, Schernthaner G, Tangri N, Garg A
Diabetes Obes Metab
. 2016 Mar;
18(6):607-14.
PMID: 26939711
Aim: To examine how antihyperglycaemic medications were prescribed to older adults with diabetes and chronic kidney disease over the last decade. Methods: We conducted a population-based study of 144 252...
5.
Brix J, Krzizek E, Hoebaus C, Ludvik B, Schernthaner G, Schernthaner G
Horm Metab Res
. 2016 Feb;
48(5):345-8.
PMID: 26882051
Recently, SFRP4 was identified as a molecular link between islet inflammation and defective insulin secretion. Gene co-expression analysis detected a molecule associated with type 2 diabetes mellitus (T2D), elevated HbA1c,...
6.
Ay L, Thaler J, Brix J, Schernthaner G, Ay C, Pabinger I, et al.
Int J Obes (Lond)
. 2015 Dec;
40(5):768-72.
PMID: 26620889
Background: Tissue factor (TF) is the main in vivo initiator of the blood coagulation cascade. Active circulating TF was detected on small, negatively charged membrane vesicles, the so-called microvesicles (MVs),...
7.
Schernthaner G, Schernthaner-Reiter M
Diabetes Obes Metab
. 2015 May;
17(7):613-5.
PMID: 26018554
No abstract available.
8.
Schernthaner G, Rosas-Guzman J, Dotta F, Guerci B, Simo R, Festa A, et al.
Diabetes Obes Metab
. 2015 Apr;
17(7):689-98.
PMID: 25846577
Aims: To evaluate third-line thiazolidinedione (TZD) or glimepiride therapy in patients inadequately controlled on metformin + exenatide twice daily, and third-line exenatide twice daily in patients inadequately controlled on metformin ...
9.
Schernthaner G, Duran-Garcia S, Hanefeld M, Langslet G, Niskanen L, Ostgren C, et al.
Diabetes Obes Metab
. 2015 Mar;
17(7):630-8.
PMID: 25761977
Aims: To assess the efficacy and safety of adjunctive saxagliptin vs glimepiride in elderly patients with type 2 diabetes (T2D) and inadequate glycaemic control. Methods: In this multinational, randomized, double-blind,...
10.
Holden S, Jenkins-Jones S, Morgan C, Schernthaner G, Currie C
Diabetes Obes Metab
. 2014 Nov;
17(4):350-62.
PMID: 25399739
Aims: To evaluate the association between insulin exposure and all-cause mortality, incident major adverse cardiovascular events (MACE) and incident cancer in people with type 2 diabetes treated with insulin monotherapy....